SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-015964
Filing Date
2021-03-29
Accepted
2021-03-29 08:01:01
Documents
12
Period of Report
2021-03-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrr-8k_20210323.htm   iXBRL 8-K 40256
  Complete submission text file 0001564590-21-015964.txt   173882

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrr-20210323.xsd EX-101.SCH 5760
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrr-20210323_lab.xml EX-101.LAB 20227
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrr-20210323_pre.xml EX-101.PRE 12072
5 EXTRACTED XBRL INSTANCE DOCUMENT tcrr-8k_20210323_htm.xml XML 3659
Mailing Address 100 BINNEY STREET CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET CAMBRIDGE MA 02142 617-949-5200
TCR2 THERAPEUTICS INC. (Filer) CIK: 0001750019 (see all company filings)

IRS No.: 474152751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38811 | Film No.: 21779515
SIC: 2836 Biological Products, (No Diagnostic Substances)